References
Falini B . Anaplastic large-cell lymphoma: pathological, molecular and clinical features. Br J Haematol 2001; 114: 741–760.
Pulford K, Falini B, Banham AH, Codrington D, Roberton H, Hatton C et al. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood 2000; 96: 1605–1607.
Mussolin L, Pillon M, d’Amore SG, Santoro N, Lombardi A, Fagioli F et al. Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large-cell lymphoma. Leukemia 2005; 19: 1643–1647.
Damm-Welk C, Busch K, Burkhardt B, Schieferstein J, Viehmann S, Oschlies I et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood 2007; 110: 670–677.
Brugieres L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G et al. Anaplastic large cell lymphoma (ALCL) in children: equal efficacy but greater toxicity of chemotherapy including methotrexate (MTX) 1g/m2 in 24 hour infusion with intra-thecal injection (IT) than chemotherapy with MTX 3g/m2 in 3 hours infusion without IT: results of the ALCL99-R1 randomised trial[abstract]. Blood 2006; 108: 122a.
Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion transcripts for residual disease detection in leukaemia—a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.
Ait-Tahar K, Bernardo MCN, Pulford K . CD4 T-Helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. Cancer Res 2007; 67: 1898–1901.
Passoni L, Gallo B, Biganzoli E, Stefanoni R, Massimino M, Di Nicola N et al. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large-cell lymphomas. Haematologica 2006; 91: 48–55.
Acknowledgements
This work was supported by Fondazione Città della Speranza.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mussolin, L., Bonvini, P., Ait-Tahar, K. et al. Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL. Leukemia 23, 400–402 (2009). https://doi.org/10.1038/leu.2008.184
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.184
- Springer Nature Limited
This article is cited by
-
Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature
Clinical Hematology International (2023)
-
Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma
International Journal of Hematology (2018)
-
Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis
Leukemia (2013)
-
Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies
Blood Cancer Journal (2012)
-
Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning for a child with recurrent anaplastic large cell lymphoma
International Journal of Hematology (2010)